These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27697594)

  • 1. Drug repurposing for glioblastoma based on molecular subtypes.
    Chen Y; Xu R
    J Biomed Inform; 2016 Dec; 64():131-138. PubMed ID: 27697594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics and mouse phenotypes.
    Chen Y; Gao Z; Wang B; Xu R
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):516. PubMed ID: 27557118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma.
    Luo D; Luo A; Hu S; Ye G; Li D; Zhao H; Peng B
    Sci Rep; 2024 Jul; 14(1):17630. PubMed ID: 39085480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma.
    Oh YT; Cho HJ; Kim J; Lee JH; Rho K; Seo YJ; Choi YS; Jung HJ; Song HS; Kong DS; Seol HJ; Lee JI; Yoon Y; Kim S; Nam DH; Joo KM
    PLoS One; 2014; 9(8):e103327. PubMed ID: 25084005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
    Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
    Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
    Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
    J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposing candidates.
    Fisher JL; Wilk EJ; Oza VH; Gary SE; Howton TC; Flanary VL; Clark AD; Hjelmeland AB; Lasseigne BN
    FEBS Open Bio; 2024 May; 14(5):803-830. PubMed ID: 38531616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.
    Sintupisut N; Liu PL; Yeang CH
    Nucleic Acids Res; 2013 Oct; 41(19):8803-21. PubMed ID: 23907387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
    Chai Y; Wang C; Liu W; Fan Y; Zhang Y
    J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
    Syafruddin SE; Nazarie WFWM; Moidu NA; Soon BH; Mohtar MA
    BMC Cancer; 2021 Jul; 21(1):850. PubMed ID: 34301218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
    Brown KE; Chagoya G; Kwatra SG; Yen T; Keir ST; Cooter M; Hoadley KA; Rasheed A; Lipp ES; Mclendon R; Ali-Osman F; Bigner DD; Sampson JH; Kwatra MM
    J Neurochem; 2015 Jun; 133(5):730-8. PubMed ID: 25598002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme.
    Zinn PO; Mahajan B; Sathyan P; Singh SK; Majumder S; Jolesz FA; Colen RR
    PLoS One; 2011; 6(10):e25451. PubMed ID: 21998659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
    Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
    Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
    Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth factor independence underpins a paroxysmal, aggressive Wnt5a
    Trivieri N; Visioli A; Mencarelli G; Cariglia MG; Marongiu L; Pracella R; Giani F; Soriano AA; Barile C; Cajola L; Copetti M; Palumbo O; Legnani F; DiMeco F; Gorgoglione L; Vescovi AL; Binda E
    J Exp Clin Cancer Res; 2022 Apr; 41(1):139. PubMed ID: 35414102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Challenges and Opportunities in Treating Glioblastoma.
    Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N
    Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.
    Alomari S; Zhang I; Hernandez A; Kraft CY; Raj D; Kedda J; Tyler B
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.
    Sathyan P; Zinn PO; Marisetty AL; Liu B; Kamal MM; Singh SK; Bady P; Lu L; Wani KM; Veo BL; Gumin J; Kassem DH; Robinson F; Weng C; Baladandayuthapani V; Suki D; Colman H; Bhat KP; Sulman EP; Aldape K; Colen RR; Verhaak RG; Lu Z; Fuller GN; Huang S; Lang FF; Sawaya R; Hegi M; Majumder S
    J Neurosci; 2015 Nov; 35(45):15097-112. PubMed ID: 26558781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.